Lacosamide Aristo (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilises neuronal membranes and reduces hyperexcitability. Additionally, it binds to the protein CRMP‑2, further modulating neuronal signalling pathways that contribute to seizure generation, thereby decreasing the likelihood of abnormal electrical activity in the brain.

The specific dose of Lacosamide Aristo is determined by the prescribing clinician based on the individual’s age, renal and hepatic function, and response to therapy. The prescriber will start with a low dose and may titrate upward to achieve optimal seizure control while monitoring for tolerability.

Lacosamide is classified as Pregnancy Category C, indicating that risk to the fetus cannot be ruled out. It should only be used if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; therefore, a healthcare professional should evaluate the risk‑benefit ratio before use in nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Compared with traditional sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation rather than fast inactivation, which may result in a different side‑effect profile and lower risk of certain cardiac effects. Unlike some newer agents, it does not require extensive titration but still needs individualized dosing based on patient response.

Lacosamide Aristo tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

The medication is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to other medicines to ensure consistent absorption.

Serious adverse events include suicidal thoughts or behaviours, severe skin reactions such as Stevens‑Johnson syndrome, and cardiac conduction abnormalities like PR‑interval prolongation. Patients should be instructed to seek immediate medical attention if they notice rash, mood changes, or symptoms such as fainting or irregular heartbeat.

Lacosamide Aristo is contraindicated in individuals with known hypersensitivity to lacosamide or any of its excipients. It should also be avoided in patients with severe cardiac conduction disorders (e.g., second‑ or third‑degree AV block) unless a pacemaker is in place, and in those where the risk‑benefit assessment is unfavorable.